gynäkologie + geburtshilfe

, Volume 22, Issue 1, pp 34–40 | Cite as

Vorgehen in der Prä- und Postmenopause

Adjuvante endokrine Therapie des Mammakarzinoms

Zertifizierte Fortbildung
  • 44 Downloads

Zusammenfassung

Bei Brustkrebspatientinnen mit Östrogen- und/oder Progesteronrezeptor-positiven Tumoren ist eine adjuvante endokrine Therapie indiziert. Neben Risikoprofil und Nebenwirkungen sollte für die Therapie der Menopausenstatus der Betroffenen Beachtung finden.

Literatur

  1. 1.
    www.awmf.org/leitlinien/detail/ll/032-045OL.html
  2. 2.
    www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/
  3. 3.
    Hammond ME et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    www.nccn.org/professionals/physician_gls/pdf/breast.pdf
  5. 5.
    Ravdin RG et al. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet. 1970;131(6):1055–64.Google Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348(9036):1189-96.Google Scholar
  7. 7.
    Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.Google Scholar
  10. 10.
    Braems G et al. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547–51.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Clemons M, Simmons C: Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat. 2007;104(2):115–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Tevaarwerk AJ et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Francis PA et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.CrossRefPubMedGoogle Scholar
  14. 14.
    Pagani O et al. Adjuvant exemestan with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gnant M et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26(2):313–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Ribi K et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016;34(14):1601–10.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim HA et al. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. BMC Cancer. 2016;16:319.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Regan MM et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Coates AS et al. Tailoring therapies — improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689–701.CrossRefPubMedGoogle Scholar
  21. 21.
    Harbeck N, Herausgeber. Zielgerichtete Therapien beim Mammakarzinom. Der Praxisguide. 1. Auflage. Stuttgart: Schattauer Verlag; 2014.Google Scholar
  22. 22.
    Ryden L et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast. 2016;26:106–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-52.Google Scholar
  24. 24.
    O'Leary CG et al. Extended adjuvant endocrine therapy in hormone receptor-positive early breast cancer. Curr Opin Oncol. 2016;28(6):455–460.CrossRefPubMedGoogle Scholar
  25. 25.
    Gray RG et al. ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(Suppl):Abstr 5.Google Scholar
  26. 26.
    Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381(9869):805–16.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Mamounas EP et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Jakesz R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG 6a). J Clin Oncol. 2005;23(16 Suppl):Abstr 527.Google Scholar
  30. 30.
    Zdenkowski N et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomized, controlled trial. Ann Oncol. 2016;27(5):806–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Goss PE et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol 2016; 34(Suppl):Abstr LBA1.Google Scholar
  32. 32.
    Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol. 2016;8(4):261–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bauerschlag DO et al. Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer. Breast Care (Basel). 2014;9(4):283–6.CrossRefGoogle Scholar
  35. 35.
    Harris LN et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134–50.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Spring LM et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin 2017

Authors and Affiliations

  1. 1.
  2. 2.Universitäts-Frauenklinik am Klinikum Südstadt RostockRostockDeutschland

Personalised recommendations